TNFRSF8 positive

P2, N=79, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028

Treatment with oral etretinate and narrowband ultraviolet B phototherapy resulted in improvement of the MF lesions, and no recurrence of the erythematous papules has been observed. As LyP may morphologically resemble cutaneous involvement of HL or MF with LCT, comprehensive evaluation, including clinical course, imaging findings, and immunophenotypic analysis, is essential for accurate diagnosis.

P3, N=120, Recruiting, Evopoint Biosciences Inc. | Not yet recruiting --> Recruiting

There are 8 patients treated with R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine combined with prednisone) for 2~9 courses, of which 3 cases had complete remission, 4 cases had partial remission, and 1 case died after treatment. O-DLBCL is mostly a centroblastic type and a non-GCB type, with high Ki67 and high dual expression ratios of Bcl-2 and C-MYC, and should be actively treated to reduce its mortality rate.

The patient received brentuximab vedotin plus cyclophosphamide, doxorubicin and prednisone (BV-CHP) chemotherapy following multidisciplinary review and showed marked improvement. This case illustrates the diagnostic challenge of ALK-positive ALCL presenting as a recurrent axillary abscess. Early recognition and histopathological evaluation of atypical or non-resolving abscesses are essential for timely diagnosis and effective treatment, ultimately improving patient outcomes.

Altogether, these findings were insufficient to establish a diagnosis of pcGDTCL. We review the clinical, histopathologic, and molecular sequencing data pertaining to our rare patient as well as the recent literature on indolent CD30+LPD with gamma-delta T-cells.

AITL with HRS-like cells is prone to misdiagnosis as CHL due to overlapping morphological and immunophenotypic features. Integration of EBER, TCR/IG clonality assessment, and molecular profiling, particularly the identification of TET2 and RHOA mutations is essential for accurate classification. Recognizing this entity is critical for avoiding diagnostic pitfalls and guiding appropriate therapeutic strategies.

The diagnosis was based on histopathological features, special stains, and immunohistochemical findings. The coexistence of these two distinct infections highlights the importance of considering multiple etiologies when evaluating reactive lymphadenopathy.

P1, N=43, Active, not recruiting, UNC Lineberger Comprehensive Cancer Center | Recruiting --> Active, not recruiting | Trial completion date: Sep 2041 --> Nov 2039 | Trial primary completion date: Sep 2026 --> Dec 2025

The index case report highlights the diagnostic complexities of the small cell variant of ALCL and emphasises the utility of various ancillary techniques like immunophenotyping and FISH, in conjunction with cytomorphology, in confirming such a challenging diagnosis.

The antibody-drug conjugate brentuximab vedotin (BV) has significantly improved outcomes for CD30-expressing lymphomas. The ECHELON-2 trial established BV combined with cyclophosphamide, doxorubicin, and prednisone (CHP) as a frontline standard for systemic anaplastic large cell lymphoma, demonstrating superior survival over the traditional CHOP regimen...We assess alternative strategies, such as BV-based combinations with immunotherapies or alternative chemotherapies, the integration of other targeted agents, and the transformative potential of advanced cellular treatments like anti-CD30 chimeric antigen receptor (CAR)-T cell therapy for relapsed/refractory disease. The collective evidence signals a paradigm shift from a one-size-fits-all approach toward personalized, precision-driven strategies aimed at maximizing efficacy, minimizing toxicity, and improving long-term quality of life for patients with CD30-positive lymphomas.